Company profile
Caribou Biosciences, Inc.
NASDAQ:CRBUBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Vispacabtagene Regedleucel | phase1 | — | 2 | unknown, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05722418 | phase1 | recruiting | 2023-02-06 | 2027-12-01 | Caribou Biosciences, Inc. | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma |
| NCT04637763 | phase1 | unknown | 2021-05-26 | 2025-08-01 | Caribou Biosciences, Inc. | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) |
| NCT06752876 | phase1 | withdrawn | 2027-12-01 | 2029-04-01 | Caribou Biosciences, Inc. | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) |
| NCT06128044 | phase1 | terminated | 2024-02-08 | 2025-05-30 | Caribou Biosciences, Inc. | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
FDA applications (0)
No records yet.